Latest News Releases

PTA-Adhoc: Biofrontera AG: Biofrontera AG announces reduction of shareholding in Biofrontera Inc. below 50%

Public disclosure of inside information according to article 17 MAR

Leverkusen (pta006/29.12.2021/10:20) - Leverkusen, Germany, December 29, 2021 - Today, Biofrontera AG (ISIN: DE0006046113), was informed by Biofrontera Inc. (Nasdaq: BFRI) that the total amount of BFRI shares outstanding has increased due to exercises of previously issued warrants. As a result, Biofrontera AG’s shareholding in Biofrontera Inc. of 8,000,000 shares now represents approximately 47 % of the currently outstanding shares.

Thus, after legal review, Biofrontera Inc. is no longer considered a subsidiary of Biofrontera AG according to § 290 HGB.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen

ISIN: DE0006046113

WKN: 604611

Contact:

Biofrontera AG

Tel: +49 (0214) 87 63 2 0, Fax: +49 (0214) 87 63 290

Email: ir@biofrontera.com

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: Nasdaq

[ source: http://www.pressetext.com/news/20211229006 ]

Biofrontera AG – an attractive investment

We are experts in photodynamic therapy. With our innovative products and treatment methods, we make our contribution to skin health and at the same time create value for our investors.

Biofrontera is listed on the Frankfurt Stock Exchange (B8F) and on the NASDAQ Stock Exchange (BFRA) in New York.